Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective study

OBJECTIVE: To evaluate the efficacy and safety of low-dose (45 mg) intravesical bacille Calmette–Guérin (BCG) therapy in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC), as intravesical BCG is the most acceptable adjuvant therapy for NMI transitional cell carcinoma of the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Nour, Hani H., Gobashy, Smair E., Kamal, Ahmad M., Elbaz, Ahmad G., Roshdy, Mamdouh A., Kamel, Ahmad I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656809/
https://www.ncbi.nlm.nih.gov/pubmed/26609440
http://dx.doi.org/10.1016/j.aju.2015.09.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656809/
https://www.ncbi.nlm.nih.gov/pubmed/26609440
http://dx.doi.org/10.1016/j.aju.2015.09.005

Ejemplares similares